HOME >> BIOLOGY >> NEWS
Pharmaceutical 'smart bomb' targets cancer cells

even in cancer cells is used as the activator. When researchers insert a gene for this enzyme into cancer cells, the cells start to express the nitroreductase, making them an easy target. The prodrug "bomb" goes off and unleashes the toxin that spreads to neighboring cells which ultimately kills the tumor.

The English contingent also developed a compound that is being evaluated in clinical trials as an anticancer prodrug. But Hu's new compounds appear to be even more potent. The overseas researchers are now testing the Rutgers compounds, side by side with their own, delivering them in the enhanced prodrug packages.

Initial testing on mammalian hamster cells shows that after 72 hours of drug exposure, the Rutgers compounds were as much as 100 times more effective in inhibiting cell growth. One-hour tests were also performed and, again, the Rutgers compounds were found to be superior as much as 30 times more effective than the English compound. Eighteen-hour tests on human ovarian cancer cells showed a still significant, tenfold superiority.

"Our cytotoxic compounds delivered to the cancer site in a revamped prodrug form clearly show great potential, but there are still lots of tests to be done," said Hu. "There are many preclinical studies ahead of us. If everything goes well, we could see clinical trials in humans in a couple of years."

Hu says that these compounds are not going to cure cancer by themselves. But they will be significant tools, most probably used in combination with other technologies one bullet of many in the arsenal of anticancer weapons.


'"/>

Contact: Joseph Blumberg
blumberg@ur.rutgers.edu
732-932-7084 Ext. 652
Rutgers, the State University of New Jersey
31-Dec-2000


Page: 1 2

Related biology news :

1. Warren Pharmaceuticals publishes results of preclinical evaluation
2. Cyclis Pharmaceuticals reports studies defining new mechanism for potential cancer therapies
3. Final results of the two Zevalin pivotal trials in radioimmunotherapy for B cell Non-Hodgkins Lymphoma announced by IDEC Pharmaceuticals
4. Pharmaceutical and personal care products: What happens when they enter the environment - an emerging concern
5. Researchers, Regulators, Industry, Consumer Advocates Gather to Discuss Critical Issues Facing the Pharmaceutical Industry
6. Ribozyme Pharmaceuticals, Inc. Demonstrates Potent Activity Of A Ribozyme Targeted Against The Hepatitis C Virus
7. Idun Pharmaceuticals Identifies Cell Type And Molecular Pathway Involved In TransplantationRelated Liver Damage
8. Cubist Pharmaceuticals Describes New VITA™ Technology For Enabling Genomics For Drug Discovery
9. Vertex Pharmaceuticals/Yale Research Team Uses Gene Knockout Mice To Establish Role Of Caspase-9 In Neuronal Cell Death Pathway
10. Micro-Plants Yield Pharmaceutical New Wave
11. Scientists At The Scripps Research Institute And R.W. Johnson Pharmaceuticals Develop New Antibacterial Agents

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/13/2018)... BASEL, Switzerland (PRWEB) , ... December 13, 2018 , ... ... 2 - First Visit (with Ethical e-CRF®): IGA first assessment performed at the site., ... folder., 4 - Central Staff Controls Photo anonymization in BOX., 5 - Photos moved ...
(Date:12/13/2018)... (PRWEB) , ... December 12, 2018 , ... Illumina, Kaiser ... kitchen this year. The San Diego-based team-building and cooking events company has hosted ... building and corporate cooking challenges. , Each group who visits receives a ...
(Date:12/10/2018)... ... December 10, 2018 , ... Nanomedical Diagnostics , leading producer ... to 9640 Towne Centre Drive, Suite 100, effectively tripling its space from 5,200 to ... and internationally, for the sales of our drug discovery platforms. We’re in the great ...
Breaking Biology News(10 mins):
(Date:12/5/2018)... ... December 05, 2018 , ... The incredible life story ... to in the European Parliament by Carlos Moedas, the European Commissioner for Research and ... and Innovation in Our Daily Lives, Commissioner Moedas spoke at length of Yousef’s life ...
(Date:11/29/2018)... ... November 29, 2018 , ... RAGS, today announced the closing of ... Fund, with participation from existing investor and board member Jeremy Andrus, CEO of Traeger ... The additional funding will enable the company to accelerate its growth and expand the ...
(Date:11/26/2018)... ... November 26, 2018 , ... USARAD Holdings ... and Omphalos Venture Partners (Virtual Radiologic founders) among other healthcare investors exhibits at ... at McCormick Place in Chicago. The company is proud to announce a 10 ...
(Date:11/20/2018)... ... 20, 2018 , ... Each year Forbes receives thousands of nominations for candidates ... performance by individuals under 30 years of age. The Forbes 30 Under 30 list ... Entertainment to Venture Capital and Science. , In 2017, Visikol CEO Dr. Michael ...
Breaking Biology Technology:
Cached News: